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Transcatheter aortic valve implantation (TAVI) is now
increasingly performed, and 30,000 patients with severe
aortic stenosis and contraindications to or high risk for
surgery have been treated so far. The technique is still in its
infancy, but evidence has rapidly accumulated through
observational studies (1), device-specific registries (2,3) or na-
tional registries (4–6), and randomized clinical trials (7,8).
The U.K. registry presented by Moat et al. (9) in this
issue of the Journal is an important contribution to our
knowledge in the field for several reasons. It is a real-life
registry that represents all cases of TAVI performed in the
United Kingdom between 2007 and 2009 in 25 accredited
centers. The U.K. investigators should be acknowledged for
being able to achieve such a level of completeness not only
in enrollment but also in the 100% recording of fatalities,
which is one of the original features of this registry.
See page 2130
This registry is also of interest because it covers a diverse
experience, which is different from published studies on
device-specific registries. In fact, the authors used all avail-
able approaches, with a preference for transfemoral at first,
as is usual, but the transapical approach and a few transax-
illary approaches were also used. The 2 types of devices
available in Europe were used in an approximately equal
manner (5). That could give a sense of what will happen in
the future when most centers will use varied devices and
approaches, as is the case in percutaneous coronary inter-
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The results in this registry were good, with a 97%
procedural success rate and an “acceptable” rate of compli-
cations when taking into account the patients characteris-
tics: stroke 4.1%; myocardial infarction 1.3%; pacemaker
24% or 7%, according to prosthesis; moderate to severe
aortic regurgitation 13.6%; and major vascular complica-
tions 8.4% in the transfemoral cohort.
These results are in line with recent series and underline
the high procedural success rate that is no doubt the product
of a combination of careful training, mostly provided today
by the companies but to be taken over in the future by the
scientific societies, and perhaps more importantly, careful
teamwork between cardiologists and surgeons. The study
here also stresses some important points for improvement in
this young method, that’s to say the need to decrease the
incidence of cerebrovascular accidents and vascular compli-
cations as well as the occurrence of moderate to severe aortic
regurgitation.
Even if Moat et al. (9) may be somewhat over-
enthusiastic by qualifying their results as “long-term out-
comes,” the results presented here are among the longest
available to us, as 2-year outcomes are available for 200
patients. Here again, the survival curves are in line with the
data available up to 2 years and beyond in the literature.
Importantly, the number of patients included and the
duration of follow-up allowed the identification of predic-
tors of midterm mortality, the first of which is cardiac: low
left ventricular ejection fraction. The data on improvement
in left ventricular function after TAVI are scarce but suggest
that TAVI may be more effective than surgery at improving
left ventricular function in patients with low ejection frac-
tion. However, this group of patients needs to be investi-
gated further as it represents, in many centers, a relative
contraindication, and these patients were excluded from the
randomized PARTNER trial (7,8). The predictive value of
flow reserve should also be explored in this context as well as
the importance of preventive coronary revascularization and
balloon valvuloplasty as a bridge to TAVI. The second
independent predictor of 1-year mortality was noncardiac:
the presence of chronic obstructive pulmonary disease. This
finding leads us to ask ourselves 2 questions. First, we
should be sure that the patient really has severe aortic
stenosis as the main causative factor and not chronic
obstructive pulmonary disease associated with only moder-
ate aortic stenosis; second, the contribution of noncardiolo-
gists is essential for patient selection to avoid performing
TAVI in patients who have limited life expectancy regard-
less of valve disease and, even more so, limited potential for
recovery after the procedure. The third predictor is a
procedural factor: presence of moderate to severe aortic
regurgitation. That has already been suggested by 2 regis-
tries (4,6) and also raises the issue of patient selection, in
particular the strategy of imaging to appropriately size the
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magnitude and location of calcification. The presence of
moderate to severe aortic regurgitation may also be due to
technical factors and is dependent on the positioning of the
valve, which will no doubt be improved in the future by
better imaging and improvements in the design of delivery
catheters and valve prostheses. It is mandatory to continue
identifying predictors of poor immediate outcome and,
perhaps even more importantly, of subsequent attrition,
which occurs frequently in the current series with fatality
rates of 30% at 2 years.
This registry, of course, has limitations, and as nicely
stated by Moat et al. (9), “Like all registries, ours is only as
good and credible as the quality of the data within it.” The
future registries should use the new VARC classification for
reporting adverse events (11), to allow for better comparison
of the outcomes between trials, in the comparison of devices
and techniques, and as a consequence better analysis of
predictors.
In conclusion, TAVI is a promising technique and the
data in this registry add a significant piece of evidence in
support of the statement that, for high-risk or inoperable
patients, when performed in properly trained centers, safety
is acceptable and midterm survival is satisfactory. All our
efforts to pursue the development of this technique should
aim at improving patient selection both by a dedicated
medicosurgical team and by improving procedural perfor-
mance through careful training and improvement in tech-
nology, and also by adequately evaluating randomized stud-
ies as well as good-quality registries that represent real life
and are a necessary complement to the former.
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